SPHS - Sophiris Bio, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.56
-0.02 (-0.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.58
Open3.58
Bid2.80 x 1000
Ask3.61 x 800
Day's Range3.47 - 3.62
52 Week Range1.80 - 3.75
Volume258,293
Avg. Volume295,124
Market Cap107.481M
Beta0.67
PE Ratio (TTM)N/A
EPS (TTM)-0.29
Earnings DateMar 26, 2018 - Mar 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.25
Trade prices are not sourced from all markets
  • Zacks Small Cap Research6 days ago

    SPHS: Countdown to Release of Topline Data for Phase 2b Study of Topsalysin in Prostate Cancer at end of 2Q18

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound has been successfully tested in one Phase 3 clinical trial for BPH and a Phase 2a clinical trial for localized prostate cancer.

  • Benzinga11 days ago

    Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 15) Inspire Medical Systems Inc (NYSE: INSP ) Aptevo Therapeutics ...

  • Sophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate Highlights
    PR Newswire13 days ago

    Sophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia , May 14, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Loss-Making Sophiris Bio Inc (NASDAQ:SPHS) Expected To Breakeven
    Simply Wall St.21 days ago

    Loss-Making Sophiris Bio Inc (NASDAQ:SPHS) Expected To Breakeven

    Sophiris Bio Inc’s (NASDAQ:SPHS): Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The US$85.49M market-cap company announced a latestRead More...

  • Zacks Small Cap Research2 months ago

    SPHS: Topline Results from Phase 2b Study of Topsalysin at end of 2Q18

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. Sophiris is currently conducting a Phase 2b clinical trial of topsalysin in patients with localized clinically significant prostate cancer (NCT03081481).

  • Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights
    PR Newswire2 months ago

    Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia , March 21, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Sophiris Bio to Present at 17th Annual Needham Healthcare Conference
    PR Newswire2 months ago

    Sophiris Bio to Present at 17th Annual Needham Healthcare Conference

    SAN DIEGO and VANCOUVER, British Columbia , March 15, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Sophiris Bio to Participate in the 10th Annual Biotech Showcase Conference
    PR Newswire5 months ago

    Sophiris Bio to Participate in the 10th Annual Biotech Showcase Conference

    SAN DIEGO and VANCOUVER, British Columbia , Dec. 27, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer
    PR Newswire5 months ago

    Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer

    SAN DIEGO and VANCOUVER, British Columbia, Dec. 11, 2017 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris") today announced that it has completed enrollment in its Phase 2b study to evaluate the safety and tolerability of topsalysin in treating men with clinically significant localized prostate cancer. "I am delighted that Sophiris has completed enrollment into its multi-center Phase 2b study. My thanks to the men and my colleagues in each clinical trial center for recognizing the potential of topsalysin to focally treat localized, clinically significant prostate cancer with a minimally invasive, targeted, short duration procedure," said Professor Hashim Ahmed, Chair of Urology, Imperial College London & Imperial College Healthcare NHS Trust and an investigator in the study.

  • Sophiris Bio to Participate in the 29th Annual Piper Jaffray Healthcare Conference
    PR Newswire6 months ago

    Sophiris Bio to Participate in the 29th Annual Piper Jaffray Healthcare Conference

    SAN DIEGO and VANCOUVER, British Columbia , Nov. 27, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.6 months ago

    Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?

    While small-cap stocks, such as Sophiris Bio Inc (NASDAQ:SPHS) with its market cap of USD $61.57M, are popular for their explosive growth, investors should also be aware of their balanceRead More...

  • SPHS: First Dosing in Phase 2b Trial of Topsalysin in Prostate Cancer Almost Complete; Data in 1H18
    Zacks Small Cap Research6 months ago

    SPHS: First Dosing in Phase 2b Trial of Topsalysin in Prostate Cancer Almost Complete; Data in 1H18

    As expected, the company did not report any revenues during the quarter. The company reported a net loss of $2.7 million, or $0.09 per share. The increase was due to costs associated with the Phase 2b trial of topsalysin in prostate cancer along with increased manufacturing costs.

  • Sophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights
    PR Newswire7 months ago

    Sophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia , Nov. 9, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Sophiris Bio Provides Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate Cancer
    PR Newswire8 months ago

    Sophiris Bio Provides Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate Cancer

    SAN DIEGO and VANCOUVER, British Columbia, Oct. 2, 2017 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris") today provided an update on clinical trial enrollment of its Phase 2b study of topsalysin as a treatment for men with clinically significant localized prostate cancer. Patient enrollment is near completion, and the remaining patients are being scheduled to receive treatment within the next few weeks. Sophiris expects the study will be fully enrolled by the end of October.

  • Sophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley Bank
    PR Newswire8 months ago

    Sophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley Bank

    SAN DIEGO and VANCOUVER, British Columbia, Sept. 13, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that it entered into a loan and security agreement with Silicon Valley Bank and may borrow up to $10 million in two term loans. "We plan to utilize the proceeds from this loan to fund the manufacturing for Phase 3 clinical trial materials and expect that it will allow us to extend our cash runway to the middle of 2019 and provide additional financial flexibility as we advance topsalysin through clinical development," said Randall E. Woods, president and CEO of Sophiris.

  • Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
    PR Newswire9 months ago

    Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 17, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference.

  • Zacks Small Cap Research9 months ago

    SPHS: Phase 2b Trial of Topsalysin in Prostate Cancer Underway

    By David Bautz, PhD NASDAQ:SPHS Financial Update On August 10, 2017, Sophiris (NASDAQ:SPHS) announced financial results for the second quarter of 2017. As expected, the company did not report any revenues ...

  • Sophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights
    PR Newswire10 months ago

    Sophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia , Aug. 10, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a late stage clinical biopharmaceutical company ...

  • Sophiris Bio Added to Russell Microcap Index
    PR Newswire11 months ago

    Sophiris Bio Added to Russell Microcap Index

    SAN DIEGO and VANCOUVER, British Columbia, June 23, 2017 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris"), a late stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases, today announced that it has been added to the Russell Microcap® Index, effective after the close of market on June 23, 2017. The Russell Microcap® Index represents 2,000 small cap and micro-cap stocks that captures the smallest 1,000 companies in the Russell 2000®, in addition to 1,000 smaller U.S.- based listed stocks. Russell indices are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.

  • Sophiris Bio Announces that the First Patient Has Been Dosed in Phase 2b Study of Topsalysin in Patients with Clinically Significant Localized Prostate Cancer
    PR Newswirelast year

    Sophiris Bio Announces that the First Patient Has Been Dosed in Phase 2b Study of Topsalysin in Patients with Clinically Significant Localized Prostate Cancer

    SAN DIEGO and VANCOUVER, British Columbia, June 8, 2017 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris") today announced that the first patient has been dosed in its Phase 2b study to evaluate the safety and tolerability of topsalysin in focally treating men with clinically significant localized prostate cancer. This Phase 2b study will build on the successful Phase 2a proof-of-concept study for the treatment of localized prostate cancer which demonstrated that a targeted intraprostatic administration of topsalysin has the potential to safely ablate prostate tumor cells. "Topsalysin has the potential to provide a much-needed opportunity to treat the patients who have clinically significant localized prostate cancer in a targeted focal manner, ablate pre-identified lesions and downgrade the patient to non-significant cancer," said Dr. Hashim Ahmed, professor and chair of urology, Imperial College London.